Skip to content

Epidemiology of Community Acquired Pneumonia in North Israel

Epidemiology of Community Acquired Pneumonia in North Israel

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00390819
Enrollment
100
Registered
2006-10-20
Start date
2006-11-30
Completion date
Unknown
Last updated
2006-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Community Acquired Pneumonia

Keywords

Community acquired pneumonia

Brief summary

Pneumonia in general and CAP in particular is considered as one of the most common bacterial infections, associated with high rates of morbidity and mortality and is highly significant economically since all respiratory infections, and pneumonia especially, cause about 80% of antimicrobials use in the community. The high frequency of respiratory infections and the excessive use of antimicrobials are major contributors to the development of pathogens resistant to antimicrobials. In addition, in CAP almost all patients are treated empirically, without identification of causing pathogen. Aim of study: To identify common pathogens causing CAP in hospitalized patients in north Israel.

Detailed description

Pneumonia in general and CAP in particular is considered as one of the most common bacterial infections, associated with high rates of morbidity and mortality. CAP is highly significant economically since all respiratory infections, and pneumonia especially, cause about 80% of antimicrobials use in the community. The high frequency of respiratory infections and the excessive use of antimicrobials are major contributors to the development of pathogens resistant to antimicrobials. In addition, in CAP almost all patients are treated empirically, without identification of causing pathogen. CAP is divided to two principal groups: Bacterial CAP and Atypical CAP. Since pathogens are different, treatment approach is also different. The main obstacle is absence of adequate diagnostic immediate and cheap tools to enable identifying pathogen and hence treatment is not always appropriate. Giving the right therapy at the right time is of major importance since early start of correct treatment is linked to morbidity and mortality of patients. For prescribing appropriate empiric therapy, knowing the epidemiology of CAP, i.e. the frequent causing pathogens according to age groups and other demographic characteristics, is essential. Unfortunately, except one study conducted 10 years ago by Dr. Liberman from Soroka Medical Center, there is no characteristic information regarding causing pathogens. Lacking this data, might result in selecting inadequate treatment. Material & Methods: We should enroll about 300 patients hospitalized in Ha'Emek Medical Center with the diagnosis of CAP, in order to make the study results statistically significant. In addition to demographic and clinical data, following tests will be performed: 1. Blood cultures 2. Sputum 3. PCR - throat culture to the following pathogens: * Mycoplasma pneumoniae * Chlamydia pneumoniae * Legionella * Adenovirus * Influenza A * Influenza B * RSV * Metapneumovirus * Parainfluenza * Pneumococcal antigen in urine

Interventions

None listed

Sponsors

HaEmek Medical Center, Israel
Lead SponsorOTHER

Study design

Observational model
DEFINED_POPULATION
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Community acquired pneumonia * Hospitalization

Exclusion criteria

* Immunocompromised patients * Patients under chemotherapy treatment * Patients under steroids treament

Countries

Israel

Contacts

Primary ContactFahmi Shibli, M.D.
fahmi_shibli@yahoo.ie972-4-6494000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026